This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06131437 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 809 participants |
| Design | Interventional, Randomized, Parallel, Masking: None |
| Conditions | Obesity |
| Interventions | Cagrilintide; Semaglutide; Tirzepatide |
| Start | Nov 27, 2023 |
| Primary completion | Dec 8, 2025 |
| Study completion | Jan 9, 2026 |
| Results posted | Not yet |
| Registry last updated | Feb 6, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight | From baseline (week 0) to end of treatment (week 84) |
14 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
